HomeNewsPress ReleaseIan Fraser appointed as Executive Vice President,...

Ian Fraser appointed as Executive Vice President, Clinical Development.

  • Published 30/03/2022
  • Categories Press Release
  • Download Download

30 March 2022. Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Ian Fraser as Executive Vice President (EVP) Clinical Development.

Ian will be leading the Clinical Development team across the global business and becomes part of the Senior Leadership Team, reporting to COO, Tom Watson.

He has extensive international experience in the pharmaceuticals and CRO industry, having worked for a decade at Chiltern as VP Clinical Operations in oncology development, and more recently, COO at Clinipace.

Tom Watson, Chief Operating Officer at Bionical Emas, said:

Ian will be leading our clinical development strategy and be responsible for delivering operational and commercial excellence and is, therefore, central to our mission of pioneering the way life-changing medicines are developed and accessed for patients around the world.

Ian’s appointment continues our investment in our people and infrastructure during this exciting phase of international growth.

Contact details

Bionical Emas
Katie Clayton, Head of Marketing
+44 (0) 1462 416435

Meare Consulting
Adrian Duffield, Managing Director
+44 (0) 7990 85 85 48

Note to Editors

Bionical Emas is a global Contract Research Organisation (CRO) business which combines clinical development, early access program and clinical trial supply capabilities to deliver a unique, seamless service for their international pharma and biotech clients. Their mission is to pioneer the way life-changing medicines are developed and accessed for patients around the world.

It’s integrated suite of services enables Bionical Emas to maximize access, collect data and generate evidence at every point along the drug development pathway, allowing them to simultaneously address the immediate and future needs of patients.

How can we support you?

Our dedicated teams of experts are on hand to help should you require any additional resource or further information about our services.

COVID-19 Guidance & Measures

A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.